| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/09/2001 | DE10004790A1 Plaster-form transdermal therapeutic system containing zaleplon, especially for use as hypnotic agent, providing safe and controlled drug delivery |
| 08/09/2001 | DE10004572A1 Neue positive allosterische AMPA-Rezeptor Modulatoren (PAARM), Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel New positive allosteric AMPA-receptor modulators (PAARM), to processes for their preparation and their use as medicaments |
| 08/09/2001 | DE10003493A1 Preparing complexes of cyclodextrin and coenzyme Q10, are useful for treating cardiac or degenerative diseases, by homogenizing starting materials with an input of energy |
| 08/09/2001 | CA2762121A1 The use of bicyclo [3.2.1]octan or kaurene for the treatment of non-insulin dependent diabetes mellitus, hypertension and metabolic syndrome |
| 08/09/2001 | CA2399792A1 Substituted amino acids as neutral sphingomyelinase inhibitors |
| 08/09/2001 | CA2399672A1 Methods and materials relating to metallocarboxypeptidase-like polypeptides and polynucleotides |
| 08/09/2001 | CA2399649A1 Methods and materials relating to leucine-rich repeat protein-like (lrr protein-like) polypeptides and polynucleotides |
| 08/09/2001 | CA2399545A1 Pyrrolo-isoquinoline and tetrahydropyrrolo-isoquinoline derivatives and their use as mediators of the 5-ht7 receptor |
| 08/09/2001 | CA2399274A1 3-aminopyrazole inhibitors of cyclin dependent kinases |
| 08/09/2001 | CA2399214A1 Novel heterocyclic amide derivatives |
| 08/09/2001 | CA2399124A1 Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid |
| 08/09/2001 | CA2399123A1 Medicament for treating aseptic inflammations containing anemonin as effective component |
| 08/09/2001 | CA2399116A1 C-4 carbonate taxanes |
| 08/09/2001 | CA2399083A1 Use of vitamin d-derivatives in the treatment of osteoporosis and related bone disorders, as well as novel vitamin d3-derivatives |
| 08/09/2001 | CA2399063A1 A method for maintaining or improving the synthesis of mucins |
| 08/09/2001 | CA2399034A1 Continuous method for preparing pharmaceutical granules |
| 08/09/2001 | CA2399026A1 Mucin-1 derived antigens and their use in immunotherapy |
| 08/09/2001 | CA2398996A1 Compounds having antitumor activity: process for their preparation and pharmaceutical compositions containing them |
| 08/09/2001 | CA2398889A1 Antisense modulation of survivin expression |
| 08/09/2001 | CA2398754A1 2-benzothiazolyl urea derivatives and their use as protein kinase inhibitors |
| 08/09/2001 | CA2398752A1 Tosylproline analogs as thymidylate synthase inhibitors |
| 08/09/2001 | CA2398678A1 Selective killing of cells by activation of double-stranded rna dependent protein kinase-pkr |
| 08/09/2001 | CA2398674A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same |
| 08/09/2001 | CA2398261A1 Treating allergic and inflammatory conditions |
| 08/09/2001 | CA2398219A1 Dual inhibitors of cholesterol ester and wax ester synthesis for sebaceous gland disorders |
| 08/09/2001 | CA2397790A1 Method of increasing alertness by administration of a vomeropherin, and vomeropherin-emitting alarm devices |
| 08/09/2001 | CA2397076A1 Novel diphenylethylene compounds |
| 08/09/2001 | CA2396782A1 Shell-and-core dosage form approaching zero-order drug release |
| 08/09/2001 | CA2396704A1 Polycyclic dianthraquinones as anti-cancer and anti-angiogenic agents |
| 08/09/2001 | CA2396197A1 Use of rofleponide in the treatment of irritable bowel syndrome (ibs) |
| 08/09/2001 | CA2369502A1 Compositions useful as inhibitors of erk |
| 08/09/2001 | CA2369079A1 Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer |
| 08/09/2001 | CA2369076A1 Pyrazole compositions useful as inhibitors of erk |
| 08/09/2001 | CA2368541A1 C10 carbamoyloxy substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368540A1 C7 carbonate substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368534A1 C7 heterosubstituted acetate taxanes as antitumor agents |
| 08/09/2001 | CA2368510A1 C7 carbamoyloxy substituted taxanes as antitumor agents |
| 08/09/2001 | CA2368502A1 C10 heterosubstituted acetate taxanes as antitumor agents |
| 08/09/2001 | CA2368151A1 C10 carbonate substituted taxanes as antitumor agents |
| 08/09/2001 | CA2367661A1 Taxane formulations having improved solubility |
| 08/08/2001 | EP1122261A2 13 and 14-membered antibacterial macrolides |
| 08/08/2001 | EP1122257A1 Benzimidazole compounds as ORL1-receptor agonists |
| 08/08/2001 | EP1122254A2 4-Sulfonamide piperidine derivatives, method for their preparation and phamaceutical compositions containing them |
| 08/08/2001 | EP1122243A1 Novel imidazoles with anti-inflammatory activity |
| 08/08/2001 | EP1121941A1 Sorbefacients and preparations for percutaneous absorption containing the same |
| 08/08/2001 | EP1121940A1 Pharmaceutical compositions comprising an antibiotic and bromhexine, and process for their preparation |
| 08/08/2001 | EP1121939A2 Treatment of osteoporosis with EP2/EP4 receptor selective agonists |
| 08/08/2001 | EP1121938A2 Prevention of sudden infant death |
| 08/08/2001 | EP1121933A1 Premixed alatrofloxacin injectable compositions |
| 08/08/2001 | EP1121932A1 Remedies for ocular diseases |
| 08/08/2001 | EP1121931A1 Controlled release oral preparations of esculetin and its derivatives |
| 08/08/2001 | EP1121930A1 Drug preparation "histochrome" for treating acute myocardial infarction and ischaemic heart diseases |
| 08/08/2001 | EP1121929A1 Drug preparation "histochrome" for treating ocular conditions |
| 08/08/2001 | EP1121928A1 "Compositions containing phytosterol and policosanol esters of fatty acids for reducing blood cholesterol and triglycerides" |
| 08/08/2001 | EP1121927A2 A composition causing different skin sensations |
| 08/08/2001 | EP1121926A1 Cosmetic preparations containing Waltheria indica extracts |
| 08/08/2001 | EP1121865A2 A medical composition for the treatment and/or prevention of malnutrition |
| 08/08/2001 | EP1121464A1 Polymorphism in a tgf-ss gene correlated to osteoporosis |
| 08/08/2001 | EP1121456A1 In vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
| 08/08/2001 | EP1121454A1 Extracellular novel rage binding protein (en-rage) and uses thereof |
| 08/08/2001 | EP1121430A1 Human isre-binding protein |
| 08/08/2001 | EP1121427A1 (mbp1) polypeptides capable of interacting with oncogenic mutants of the p53 protein |
| 08/08/2001 | EP1121419A1 Tnfr related gene 12 |
| 08/08/2001 | EP1121376A1 Pregnane glucuronides |
| 08/08/2001 | EP1121375A1 High purity composition comprising (7alpha,17alpha)- 17-hydroxy- 7-methyl- 19-nor-17-pregn- 5(10)-en-20-yn-3-one |
| 08/08/2001 | EP1121374A1 Bone morphogenic protein-induced genes and polypeptides, and their use in diagnostic and therapeutic methods |
| 08/08/2001 | EP1121372A1 Adenine derivatives |
| 08/08/2001 | EP1121369A1 Ribavirin-interferon alfa combination therapy for eradicating detectable hcv-rna in patients having chronic hepatitis c infection |
| 08/08/2001 | EP1121366A1 Prodrugs of phosphorous-containing pharmaceuticals |
| 08/08/2001 | EP1121363A2 6-SUBSTITUTED PYRAZOLO 3,4-d]PYRIMIDIN-4-ONES USEFUL AS CYCLIN DEPENDENT KINASE INHIBITORS |
| 08/08/2001 | EP1121362A1 Imidazo-benzazepines having cardiovascular, antitumor, antiinfective and antiinflammatory activity |
| 08/08/2001 | EP1121361A1 Pyrazolo-triazine derivatives as ligands for gaba receptors |
| 08/08/2001 | EP1121360A1 Il-8 receptor antagonists |
| 08/08/2001 | EP1121359A1 Imidazo-isoquinoline compounds, their compositions and uses |
| 08/08/2001 | EP1121358A1 Heterocyclylaminomethyloxazolidinones as antibacterials |
| 08/08/2001 | EP1121356A1 3-tetrahydropyridin-4-yl indoles for treatment of psychotic disorders |
| 08/08/2001 | EP1121355A1 Quinoline derivatives and their use as antibacterial agents |
| 08/08/2001 | EP1121354A1 N-(imidazolylalkyl)substituted cyclic amines as histamine-h 3? agonists or antagonists |
| 08/08/2001 | EP1121353A1 Benzazine derivatives as phosphodiesterase 4 inhibitors |
| 08/08/2001 | EP1121351A2 Preparation of (s)-2-amino-6,6-dimethoxyhexanoic acid methyl ester via novel dioxolanes |
| 08/08/2001 | EP1121349A1 Substituted thiadiazolsulfonamides used as interleukin-1-beta inhibitors |
| 08/08/2001 | EP1121348A1 Azadioxacycloalkene derivatives, methods for the production thereof and their use as fungicides and pest control agents |
| 08/08/2001 | EP1121346A1 New processes for producing beta-alanine derivative |
| 08/08/2001 | EP1121345A1 Esters of (+)-alpha-( 2,3- dimethoxyphenyl) -1- 2-(4- fluorophenyl) ethyl]-4- piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 110,907 |
| 08/08/2001 | EP1121342A1 Diaminopropionic acid derivatives |
| 08/08/2001 | EP1121152A1 Combination of norpregnane derivatives and cyclodextrin |
| 08/08/2001 | EP1121146A2 Utilization of proteolytic enzymes to influence hyperactive t cells |
| 08/08/2001 | EP1121141A2 Angiogenically effective unit dose of fgf and method of administering |
| 08/08/2001 | EP1121139A1 Natural formulation for the treatment and prevention of depression, containing st john's wort and derivatives of dihydro- and tetrahydrofolic acid |
| 08/08/2001 | EP1121138A2 Compositions for the treatment of atherosclerosis and related conditions |
| 08/08/2001 | EP1121134A1 Derivatives of erythromycin, clarithromycin, roxithromycin or azithromycin with antibiotic and mucolytic activity |
| 08/08/2001 | EP1121133A1 Methods for stimulating bone formation |
| 08/08/2001 | EP1121132A1 Method and compositions for increasing bone mass |
| 08/08/2001 | EP1121131A2 Atypical antipsychotic in combination with acetylcholinesterase inhibitor for improving cognition |
| 08/08/2001 | EP1121130A2 Zinc finger-reactive antimicrobial compounds |
| 08/08/2001 | EP1121129A1 METHOD FOR TREATING DIABETES EMPLOYING AN aP2 INHIBITOR AND COMBINATION |
| 08/08/2001 | EP1121128A1 A method of modulating ion channel functional activity |
| 08/08/2001 | EP1121127A1 Oral pharmaceutical compositions containing buprenorphin |
| 08/08/2001 | EP1121126A1 Method for treating schizophrenia and means used in said method |
| 08/08/2001 | EP1121125A1 Pharmaceutical formulations for use in estrogen deprivation syndrome |